Insulin-like growth factor type 1 (IGF1) is a mediator of growth hormone (GH) action, and therefore, IGF1 is a candidate gene for recombinant human GH (rhGH) pharmacogenetics. Lower serum IGF1 levels were found in adults homozygous for 19 cytosine-adenosine (CA) repeats in the IGF1 promoter. The aim of this study was to evaluate the influence of (CA)n IGF1 polymorphism, alone or in combination with GH receptor (GHR)-exon 3 and À202 A/C insulin-like growth factor binding protein-3 (IGFBP3) polymorphisms, on the growth response to rhGH therapy in GH-deficient (GHD) patients. Eighty-four severe GHD patients were genotyped for (CA)n IGF1, À202 A/C IGFBP3 and GHR-exon 3 polymorphisms. Multiple linear regressions were performed to estimate the effect of each genotype, after adjustment for other influential factors. We assessed the influence of genotypes on the first year growth velocity (1st y GV) (n ¼ 84) and adult height standard deviation score (SDS) adjusted for target-height SDS (AH-TH SDS) after rhGH therapy (n ¼ 37). Homozygosity for the IGF1 19CA repeat allele was negatively correlated with 1st y GV (P ¼ 0.03) and AH-TH SDS (P ¼ 0.002) in multiple linear regression analysis. In conjunction with clinical factors, IGF1 and IGFBP3 genotypes explain 29% of the 1st y GV variability, whereas IGF1 and GHR polymorphisms explain 59% of final height-target-height SDS variability. We conclude that homozygosity for IGF1 (CA)19 allele is associated with less favorable short-and long-term growth outcomes after rhGH treatment in patients with severe GHD. Furthermore, this polymorphism exhibits a non-additive interaction with À202 A/C IGFBP3 genotype on the 1st y GV and with GHR-exon 3 genotype on adult height.
Introduction
Severe growth hormone (GH) deficiency (GHD) is a rare condition, with an estimated incidence of around 1:50 000 people per year. 1 In this condition, GH secretion is virtually absent and spontaneous growth is profoundly impaired. Without treatment, adult heights remain 4-6 standard deviation scores (SDS) below the mean for sex-matched individuals. 2 Although it is expected that hormone replacement restores the growth impairment of these children, growth responses to recombinant human GH (rhGH) are highly variable; even in patients treated according to standard recommendations. 3 As a result, some children fail to reach their target height, despite appropriate treatment for a long period of time. [4] [5] [6] A number of growth prediction models in response to rhGH therapy in patients with GHD have been proposed, but the current predictive power is insufficient to allow clinical application, suggesting that further parameterssuch as genetic factors-may be missing from existing models. [7] [8] [9] [10] In the past 5 years, it has been shown that children homozygous or heterozygous for the GH receptor (GHR)-exon 3-deleted (GHRd3) isoform have slightly better short-and long-term growth outcomes after rhGH therapy than children homozygous for the full-length GHR isoform (GHR fl). [11] [12] [13] Recently, a single-nucleotide polymorphism located at position À202 of the insulin-like growth factor binding protein-3 (IGFBP3) promoter region has been involved in rhGH pharmacogenetics: GHD patients who were homozygous for the A allele displayed better first year growth velocity (1st y GV) than patients with at least one C allele. 14 Insulin-like growth factor type 1 (IGF1; OMIM*147440) is one of the major effectors of growth-promoting actions mediated by GH, acting by both endocrine (circulating) and paracrine (local) mechanisms. 15 In addition, IGF1 serum levels are highly heritable, as shown by twin studies. 16, 17 Thus, IGF1 is an additional candidate gene for rhGH pharmacogenetic studies. Among common variants in IGF1 gene, genotypic variation at a microsatellite-named cytosine-adenosine (CA)n IGF1 repeat (D12S0043i; UniSTS 49688) has been associated with IGF1 serum levels in non-GHD adults. [18] [19] [20] This microsatellite is a short tandem repeat locus, composed of variable CA repeats located at the IGF1 promoter region, approximately 1 kb upstream from the transcription start site. The number of CA repeats ranges between 10 and 24. In the Caucasian population, the most common allele contains 19CA repeats, which corresponds to fragments of 192 bp after amplification according to standard protocols. 21 It has been reported that individuals who are homozygous for the wild-type allele (19CA repeats) present lower IGF1 serum levels after adjustment for sex and age than patients with any other genotype. 19, 20 Considering that the (CA)n IGF1 promoter genotype could influence the growth responsiveness to rhGH therapy, the objective of this study was to assess the influence of this microsatellite on growth responses to rhGH therapy in a cohort of severe GHD children. To expand the knowledge about gene-gene interactions involved in rhGH responsiveness, we have also examined the interaction of the (CA)n IGF1 variant with GHR-exon 3 and the À202 A/C IGFBP3 genotypes upon linear growth responses to rhGH.
Subjects and methods

Subjects
Informed consent and approval by the Hospital Ethics Committee were obtained before initiating the molecular studies. All patients have been treated with rhGH according to standard recommendations. Eighty-four severe GHD patients who remained prepubertal throughout the first year of rhGH therapy were selected for evaluation of the 1st y GV. Among these patients, 37 have already reached adult height after 8±3 years of rhGH treatment and were also analyzed with regard to adult height outcomes. Part of this cohort had been reported previously. 11, 14 GHD diagnosis was based on clinical and auxological parameters, as well as on the failure of GH response on at least two provocative tests, mostly insulin and clonidine. 22 Patients with central nervous system tumors, meningoencephalocele or previous radiation therapy were not included. Imaging of the hypothalamic-pituitary region was performed in all patients. According to clinical follow-up as well as the basal levels and hormonal response to the combined test (insulin þ thyrotropin-releasing hormone þ gonadotropin-releasing hormone), patients were classified as isolated GHD or combined pituitary hormone deficiency (CPHD). 23 Patients with CPHD were on adequate replacement therapy for the other hormonal deficiencies.
GH therapy
All children were treated with rhGH administered subcutaneously in a daily schedule at a mean dose of 33 mg per kg per day, which was adjusted according to changes in weight at each visit, every 3 or 4 months. Evaluations were performed at the same period of the day and included measurements of weight (measured with a digital scale) and standing height (measured with a stadiometer). Height was expressed as SDS. 24 First year GV was determined after an observation period of at least 11 months. Pretreatment GV was not available owing to the severity of short stature in the majority of patients and the prompt diagnosis of GH deficiency. Treatment was usually initiated before the minimum observation period necessary to calculate a reliable GV.
IGF1 measurements were obtained at the start of treatment and near the end of the first year of rhGH therapy. Criteria for discontinuation of rhGH treatment were GV less than 2 cm year À1 observed during a minimum 6 months of follow-up. Target height was calculated ((father's height þ mother's height þ 13 cm for boys or À13 cm for girls)/2) and expressed as SDS. Left-hand and wrist X-rays for bone age determination were assessed by the Greulich and Pyle method. 25 Hormone assays GH was measured by immunoradiometric, immunofluorometric (IFMA) or chemiluminescent (CLIA) assays (54, 36 and 10% of the patients, respectively) with monoclonal antibodies. The assays were standardized with the international standard 80/505 of the World Health Organization.
The detection limit of these assays was 0.01 mg l À1 and the intra-assay coefficient of variation was lower than 6% in the working range of the standard curve (0.1-36 mg l À1 ). Cutoff levels used for GHD diagnosis were peak GH levels o5.0 mg l À1 (immunoradiometric) or o3.3 mg l À1 (immunofluorometric and chemiluminescent).
22 IGF1 was measured by radioimmunoassay after ethanol extraction (Diagnostic Systems Laboratories-DSL, Webster, TX, USA) (84% of patients) or by chemiluminescence assays (IMMULITE, Diagnostic Products Corporation (DPC), Los Angeles, CA, USA) (16% of patients). IGF1 levels were expressed as SDS for age and sex according to reference values provided by the respective assay kits.
Molecular studies
Genomic DNA was isolated from peripheral blood leukocytes by standard methods from all patients. PCR was performed using oligonucleotide primers designed to amplify the polymorphic (CA)n repeat 1 kb upstream of the human IGF1 gene, as described previously. 26, 27 Forward primers were labeled with fluorochrome to determine the size of PCR products by fragment analysis on an automated sequencing apparatus (Gene Scan Software, Applied Biosystems, Foster City, CA, USA). Sequence analysis showed that fragments with 192 bp corresponds to the 19CA repeat genotype. In addition, all selected patients have been genotyped for the presence or absence of GHR-exon 3 and for À202 A/C IGFBP3 polymorphisms, according to previously reported protocols. 11, 14, 28 Statistical analysis Growth responses to rhGH treatment were evaluated by 1st y GV and adult height adjusted for target height (adult height SDSÀtarget-height SDS). Patients were also compared by genotype with regard to IGF1 SDS serum levels before and during treatment. Qualitative variables are listed as frequencies and percentages, whereas quantitative variables are shown as mean±s.d.
Genotype-group comparisons were performed according to a recessive genetic model of the wild-type allele, as adopted by previous studies that evaluated the effects of (CA)n IGF1 polymorphism. 19, 20, 29, 30 Thus, patients homozygous for the 19CA allele (19CA/19CA group) were compared with patients carrying one or two non-19CA alleles (non-19CA/* group).
Comparisons were made by unpaired t-test or MannWhitney rank-sum test for numerical variables and w 2 or Fisher's exact test for nominal variables, as appropriate. To assess whether genetic variants had independent influence on growth response variables, we performed single followed by multiple regression analyses adjusting for established clinical influential factors, associated with GHR-exon 3 and À202 A/C IGFBP3 genotypes. 31, 32 The evaluated clinical factors included chronological age, bone age, height, body mass index at the start of treatment, target height, isolated or CPHD, induced or spontaneous puberty, age and height at the start of puberty, rhGH doses and duration of treatment. A P-valueo0.05 was considered statistically significant. All statistical analyses were performed with SigmaStat for Windows (version 3.5; SPSS, San Rafael, CA, USA).
Results
Patients' phenotype at the start of therapy Eighty-four prepubertal GHD children (56 boys and 28 girls) were evaluated. At the start of treatment, they presented a chronological age of 8.2 ± 4.2 years, with marked bone age delay (BA ¼ 3.8±2.5 years) and short stature (height SDS ¼ À4.2 ± 1.4). Severe GHD was shown by extremely low GH peak levels, obtained after two different stimulation tests (mean GH
À1
). Eighty-nine percent of patients had either a defined genetic etiology for GHD (12 patients) or a congenital anatomic abnormality of the pituitary gland on magnetic resonance imaging (stalk interruption and/or ectopic posterior pituitary in 59 patients). Thirty-four patients presented isolated GHD and 50 had CPHD. Among patients with CPHD, 92% had hypothyroidism, 50% had hypocortisolism, 60% had hypogonadism and 14% had diabetes insipidus. All of them were adequately replaced for these hormone deficiencies. Patients with isolated GHD or CPHD, as well as patients with spontaneous or induced puberty, had similar growth outcomes with rhGH therapy (Table 1 ) and, therefore, were analyzed together.
Genotyping distribution of (CA)n IGF1 repeat The 19CA repeat allele was the most frequent (54%), in accordance with previous studies. 20, 27 With regard to genotype frequencies, 28% of patients were homozygous for the 19CA allele, 55% were heterozygous and 17% were non-carriers of the 19CA allele, frequencies that conformed to the Hardy-Weinberg equilibrium test.
Genotypic groups were similar with concern to gender distribution, isolated or combined GHD, GH peak, chronological age and bone age delay at the start of treatment, basal height SDS, parental height, spontaneous or induced puberty, age at puberty onset and mean rhGH dose (Table 2) . Among the 37 patients who had already reached adult height, those who were homozygous for the 19CA allele had been treated for a longer period than patients with other genotypes (treatment duration ¼ 10.2 ± 3.2 vs 7.9 ± 2.7 years, respectively, P ¼ 0.03) ( Table 3) .
Clinical correlations (a) 1st y GV: Patients homozygous for the 19CA allele showed lower GVs in the first year of rhGH treatment when compared with patients with at least one variant allele (non-19CA/* genotype group) ( Table 2) . As a group, patients with the 19CA/19CA genotype had GV on average 1.2 cm year À1 lower than patients with other (CA)n genotypes. Multiple linear regressions adjusting for other clinical variables showed that IGF1 genotype was an independent influential factor on the 1st year GV. Taken together with bone age (Po0.001) and height SDS (P ¼ 0.02) at the start of therapy, IGF1, IGFBP3 and GHR polymorphisms and GH pharmacogenetics EF Costalonga et al (CA)n IGF1 genotype (P ¼ 0.03) explained 20% of 1st year GV variability.
Combined analysis including IGF1, GHR and IGFBP3 genotypes showed that (CA)n IGF1 and À202 A/C IGFBP3 genotypes had an independent and interactive influence on the 1st y GVs. Patients presenting the combination of the two favorable genotypes (IGF1 non-19CA/* and IGFBP3 A/A) had 1st y GVs on average 3.2 cm year À1 higher than individuals with unfavorable combined genotypes (IGF1 19CA/19CA and IGFBP3 C/*; 95% confidence interval: 1.6-4.9 cm year À1 , Po0.001), whereas patients with intermediate genotypes (IGF1 19CA/19CA and IGFBP3 A/A or IGF1 non19CA/* and IGFBP3 C/*) had in-between values (Figure 1 ). Alone, (CA)n IGF1 genotype accounted for 4% of 1st y GV variation, whereas IGFBP3 genotype accounted for 12%. In combination, these two variants accounted for 15% Abbreviations: CA, cytosine-adenosine; CPHD, combined pituitary hormone deficiency; GHD, growth hormone deficiency; IGF1, Insulin-like growth factor type 1; IGHD, isolated growth hormone deficiency; NS, not significant; rhGH, recombinant human growth hormone; SDS, standard deviation score.
of 1st y GV variation (Po0.001) and, together with bone age (P ¼ 0.001) and height SDS (P ¼ 0.02) at the start of therapy, explained 29% of 1st year GV variability in this group of prepubertal severe GHD children. There was no significant relationship between (CA)n IGF1 microsatellites and circulating IGF1 levels, either at baseline (IGF1 SDS of À2.1±0.8 and À2.5±1.1 for 19CA/19CA group and non-19CA/* group, respectively) or during the first year of rhGH treatment (19CA/19CA group ¼ À0.6 ± 1.4; non-19CA/* group ¼ À0.3±1.5).
(b) Adult height: Despite having been treated for a longer period of time (Table 3) , patients homozygous for the 19CA allele reached lower adult height SDS adjusted for targetheight SDS (À0.6 ± 1.2) than patients from the non-19CA/* genotype group ( þ 0.4 ± 1.1; 95% confidence interval: 0.15-1.9; P ¼ 0.02; Table 3 and Figure 2 ). The influence of IGF1 genotype was independent of other influential variables, as shown by multiple regression analysis. Taken together with rhGH dose (Po0.001) and height SDS at the start of puberty (P ¼ 0.04), (CA)n IGF1 genotype (P ¼ 0.002) explained 54% of the observed variation.
Combined analysis including IGF1, GHR and IGFBP3 genotypes showed that (CA)n IGF1 and GHR-exon 3 genotypes interactively influence the adjusted adult height SDS. Patients with the combination of the two favorable genotypes (IGF1 non19CA/* and GHRd3/*) reached adult height adjusted for target height on average 1. genotype accounted for 15% of adjusted adult height SDS variation (P ¼ 0.02), whereas GHR-exon 3 genotype accounted for 13% (P ¼ 0.02). Combined, these two variants accounted for 23% of adjusted adult height SDS variation (Po0.001) and, together with mean rhGH doses (Po0.001) and height SDS at puberty onset (P ¼ 0.03), explained 59% of observed variation.
Discussion
Recent rhGH pharmacogenetic studies introduced the important concept that common variants of genes involved in the GH-IGF1 axis-such as GHR-exon 3 and À202 A/C IGFBP3-may play a role in predicting response to rhGH treatment in children with GHD. [12] [13] [14] 33 Given the central role played by the IGF system in postnatal growth and the mediation of GH actions, IGF1 is an additional candidate Figure 1 Combined effect of À202 A/C insulin-like growth factor binding protein-3 (IGFBP3) and cytosine-adenosine (CA)n insulin-like growth factor type 1 (IGF1) genotypes on the first year growth velocity after recombinant human growth hormone (rhGH) treatment in children with severe GH-deficient (GHD) (**t-test between extreme groups; *one-way analysis of variance). Figure 3 Combined effect of GH receptor (GHR)-exon 3 and cytosineadenosine (CA)n insulin-like growth factor type 1 (IGF1) genotypes on the adult height standard deviation score (SDS) adjusted for targetheight SDS after long-term recombinant human growth hormone (rhGH) treatment (**t-test between extreme groups; *one-way analysis of variance).
gene for the study of genetic variables that influences the growth response to rhGH.
In this study, we evaluated for the first time the effect of a microsatellite in the IGF1 promoter region ((CA)n IGF1) on the short-term (1st y GV) and long-term (adult stature adjusted for target height) growth responses to exogenous rhGH in a cohort of individuals with stringently defined GHD. In this cohort, homozygosity for the allele with 19CA repeats was associated with a less favorable short-and longterm growth response to rhGH therapy when compared with the presence of other genotypes. This association was independent of other influential factors, as shown by multiple linear regression analysis. This particular microsatellite is located at a region known to contain specific regulatory elements of the IGF1 gene. Thus, it is conceivable that allelic variation in this region could lead to changes in the promoter activity. However, given the association-based approach of current studies, a direct effect of this polymorphism cannot be determined and the possibility of this variant being in linkage disequilibrium with another variant, which is directly functional cannot be ruled out.
No correlation between IGF1 genotype and IGF1 serum levels was observed in this study. Statural growth depends on both endocrine and paracrine and IGF1 actions, and circulating levels may not reflect the actual IGF1 concentrations at local tissues. Furthermore, circulating IGF1 levels is influenced by many other environmental and methodological variables, 34 which brings additional complexity for statistical analysis.
Considering that epistatic interactions among common variants contribute to the determination of complex traits, 35, 36 an important point of this study was the evaluation of the combined impact of genotypes at different loci on the magnitude of growth response to rhGH therapy in these children. Such analysis showed the presence of independent and non-additive interactions between these polymorphisms. (CA)n IGF1 and À202 A/C IFGBP3 genotypes were the most important genetic determinants for the 1st y GV, accounting for 29% of variability when analyzed together with clinical factors. On the other hand, adult height was determined mostly by (CA)n IGF1 and GHR-exon 3 genotypes, which accounted for 59% of variability in this cohort of severe GHD children.
In conclusion, we describe an association between the polymorphic CA repeat in the IGF1 promoter region and the short-and long-term growth responses to rhGH in patients with severe GHD. Results of combined analyses with GHR-exon 3 and À202 A/C IGFBP3 genotypes provide another step toward the knowledge of gene-gene interactions in rhGH pharmacogenetics. Further studies will help to better understand the molecular basis of the wide range of clinical responsiveness to rhGH, thus improving prediction models and resulting in a better individualization of rhGH treatment.
